Clinical trial · Interventional
Creation of a Normal Database for FluoroDeoxyGlucose-Positron Emission Tomography (FDG-PET) Neurological Examinations
Creation of a Normal Database for FluoroDeoxyGlucose-Positron Emission Tomography (FDG-PET) Neurological Examinations: Study of Principal Inter-individual Variation Factors
NCT02858167CI-TRIAL-00023879BDD TEP FDGcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to define a reference population for FDG-PET neurological examinations starting from patients having FDG-PET to supervise a non-complicated lymphoma (tumor in remission, low disabling chronic tumor).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FDG-PET | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- FDG-PET
- interventionNames
- Device: FDG-PET
Primary outcomes (7)
- measure
- Absence of neurological impairment detected during standard neurological examination
- timeFrame
- Day 0
- measure
- Mini-mental state score
- timeFrame
- Day 0
- measure
- Frontal Assessment Battery score
- timeFrame
- Day 0
- measure
- Mini International Neuropsychiatric Interview (DSM-IV) score
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with tumor in remission or low disabling chronic tumor * No parenteral chemotherapy for at least 1 month * No glucocorticoid treatment * No general health modification (asthenia, anorexia, weight reduction) Exclusion Criteria: * Patient having a known neurodegenerative disorder, a general disease or physical problems that can interfere with cognitive function * Patient with cerebral pathology history (epilepsy, vascular event, cerebral vascular malformation, tumor, severe cranial trauma, meningitis or infectious or inflammatory encephalitis, hydrocephalus, mental retardation…) * Patient not having at least 4 years of education * Patient having an anxiolytic or anti-depressive treatment * Patient refusing to participate to the study * Patient incapable to give informed consent (guardianship)
References
Publications (0)
Data not yet available
No reference posted for this study.